Susquehanna International Group’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-76,709
| Closed | -$228K | – | 10577 |
|
|
2016
Q3 | $228K | Sell |
76,709
-27,941
| -27% | -$48.4K | ﹤0.01% | 7379 |
|
|
2016
Q2 | $156K | Buy |
104,650
+58,517
| +127% | +$134K | ﹤0.01% | 7799 |
|
|
2016
Q1 | $171K | Sell |
46,133
-105,965
| -70% | -$656K | ﹤0.01% | 8105 |
|
|
2015
Q4 | $1.54M | Buy |
152,098
+116,907
| +332% | +$1.41M | ﹤0.01% | 4575 |
|
|
2015
Q3 | $479K | Buy |
35,191
+2,133
| +6% | +$38K | ﹤0.01% | 7209 |
|
|
2015
Q2 | $627K | Sell |
33,058
-115,582
| -78% | -$2.5M | ﹤0.01% | 7181 |
|
|
2015
Q1 | $3.89M | Sell |
148,640
-136,828
| -48% | -$3.48M | ﹤0.01% | 3118 |
|
|
2014
Q4 | $5.98M | Buy |
+285,468
| New | +$7.19M | ﹤0.01% | 2647 |
|
|
2014
Q3 | – | Sell |
-33,210
| Closed | -$1.03M | – | 10355 |
|
|
2014
Q2 | $1.06M | Sell |
33,210
-282,202
| -89% | -$10.5M | ﹤0.01% | 5926 |
|
|
2014
Q1 | $14.5M | Buy |
315,412
+289,935
| +1,138% | +$17M | 0.01% | 1588 |
|
|
2013
Q4 | $1.81M | Sell |
25,477
-200,256
| -89% | -$15.3M | ﹤0.01% | 4463 |
|
|
2013
Q3 | $19.3M | Buy |
225,733
+12,167
| +6% | +$1.03M | 0.01% | 1233 |
|
|
2013
Q2 | $13.5M | Buy |
+213,566
| New | +$11.3M | 0.01% | 1458 |
|
Susquehanna International Group's AEGR Position: Q4 2016 in Review
Susquehanna International Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 76,709 shares — an estimated $228K sold.
Susquehanna International Group first reported a position in AEGR in Q2 2013 and held it in 13 quarters. The position peaked at $19.3M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Susquehanna International Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Susquehanna International Group sold 76,709 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $228K.
- Susquehanna International Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
- Susquehanna International Group's Aegerion Pharmaceuticals position peaked at $19.3M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Susquehanna International Group's 13F filing for Q4 2016, filed 14 Feb 2017.